Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Subcutaneous Rituximab for the Treatment of B-Cell Hematologic Malignancies: A Review of the Scientific Rationale and Clinical Development
Andrew Davies, Claude Berge, Axel Boehnke, et al.
Advances in Therapy (2017) Vol. 34, Iss. 10, pp. 2210-2231
Open Access | Times Cited: 55

Showing 1-25 of 55 citing articles:

Rituximab in B-Cell Hematologic Malignancies: A Review of 20 Years of Clinical Experience
Gilles Salles, Martin Barrett, Robin Foà, et al.
Advances in Therapy (2017) Vol. 34, Iss. 10, pp. 2232-2273
Open Access | Times Cited: 507
Past, Present, and Future of Rituximab—The World’s First Oncology Monoclonal Antibody Therapy
Timothy M. Pierpont, Candice B. Limper, Kristy L. Richards
Frontiers in Oncology (2018) Vol. 8
Open Access | Times Cited: 317
Preemptive rituximab prevents long-term relapses in immune-mediated thrombotic thrombocytopenic purpura
Matthieu Jestin, Y. Benhamou, An‐Sofie Schelpe, et al.
Blood (2018) Vol. 132, Iss. 20, pp. 2143-2153
Open Access | Times Cited: 130
Anti-CD20 monoclonal antibodies: reviewing a revolution
Joshua Casan, Jonathan Wong, Melissa Northcott, et al.
Human Vaccines & Immunotherapeutics (2018) Vol. 14, Iss. 12, pp. 2820-2841
Open Access | Times Cited: 94
Broadly Neutralizing Antibodies for HIV Prevention
Shelly Karuna, Lawrence Corey
Annual Review of Medicine (2020) Vol. 71, Iss. 1, pp. 329-346
Closed Access | Times Cited: 58
Subcutaneous Rituximab-MiniCHOP Compared With Subcutaneous Rituximab-MiniCHOP Plus Lenalidomide in Diffuse Large B-Cell Lymphoma for Patients Age 80 Years or Older
Lucie Obéric, Frédéric Peyrade, Mathieu Puyade, et al.
Journal of Clinical Oncology (2021) Vol. 39, Iss. 11, pp. 1203-1213
Open Access | Times Cited: 55
Humanistic and Economic Impact of Subcutaneous Versus Intravenous Administration of Oncology Biologics
Kenneth C. Anderson, Ola Landgren, Rebecca C. Arend, et al.
Future Oncology (2019) Vol. 15, Iss. 28, pp. 3267-3281
Open Access | Times Cited: 50
Efficacy, pharmacokinetics and safety of subcutaneous versus intravenous CT-P13 in rheumatoid arthritis: a randomized phase I/III trial
René Westhovens, Piotr Wiland, Marek Zawadzki, et al.
Lara D. Veeken (2020) Vol. 60, Iss. 5, pp. 2277-2287
Open Access | Times Cited: 46
Anti-CD20 treatment for B-cell malignancies: current status and future directions
Christian Klein, Candice Jamois, Tina Nielsen
Expert Opinion on Biological Therapy (2020) Vol. 21, Iss. 2, pp. 161-181
Open Access | Times Cited: 43
Australian and New Zealand consensus statement on the management of lymphoma, chronic lymphocytic leukaemia and myeloma during the COVID‐19 pandemic
Pietro R Di Ciaccio, Georgia McCaughan, Judith Trotman, et al.
Internal Medicine Journal (2020) Vol. 50, Iss. 6, pp. 667-679
Closed Access | Times Cited: 41
<p>How the discovery of rituximab impacted the treatment of B-cell non-Hodgkin&rsquo;s lymphomas</p>
Raihan Mohammed, Artemis Milne, Kayani Kayani, et al.
Journal of Blood Medicine (2019) Vol. Volume 10, pp. 71-84
Open Access | Times Cited: 38
Phase I Study of Subcutaneous Rituximab Hyaluronidase Combined With CHOP Chemotherapy for the Treatment of Diffuse Large B-Cell Lymphoma in Uganda
Manoj Menon, Henry Ddungu, Kelvin Roland Mubiru, et al.
JCO Global Oncology (2025), Iss. 11
Open Access
Assessing the transition from intravenous to subcutaneous delivery of rituximab: Benefits for payers, health care professionals, and patients with lymphoma
Michael J. Harvey, Yi Zhong, Eric Morris, et al.
PLoS ONE (2022) Vol. 17, Iss. 1, pp. e0261336-e0261336
Open Access | Times Cited: 16
Subcutaneous Antibiotic Therapy: The Why, How, Which Drugs and When
Virgilio Hernández‐Ruiz, E. Forestier, G. Gavazzi, et al.
Journal of the American Medical Directors Association (2020) Vol. 22, Iss. 1, pp. 50-55.e6
Open Access | Times Cited: 23
Population pharmacokinetic and exposure–response analyses of intravenous and subcutaneous rituximab in patients with chronic lymphocytic leukemia
Ekaterina Gibiansky, Leonid Gibiansky, Clarisse Chavanne, et al.
CPT Pharmacometrics & Systems Pharmacology (2021) Vol. 10, Iss. 8, pp. 914-927
Open Access | Times Cited: 13
Safety of switching from intravenous to subcutaneous rituximab during first‐line treatment of patients with non‐Hodgkin lymphoma: the Spanish population of the MabRella study
Ricardo García‐Muñoz, Cristina Quero, Ernesto Pérez Persona, et al.
British Journal of Haematology (2019) Vol. 188, Iss. 5, pp. 661-673
Open Access | Times Cited: 14
Comparison of Access to Novel Drugs for Lymphoma and Chronic Lymphocytic Leukemia Between India and the United States
Vishwanath Sathyanarayanan, Christopher R. Flowers, Swaminathan P. Iyer
JCO Global Oncology (2020), Iss. 6, pp. 1124-1133
Open Access | Times Cited: 14
Hyaluronidase Coated Molecular Envelope Technology Nanoparticles Enhance Drug Absorption via the Subcutaneous Route
Ramesh Soundararajan, George Wang, Asya Petkova, et al.
Molecular Pharmaceutics (2020) Vol. 17, Iss. 7, pp. 2599-2611
Open Access | Times Cited: 13
Anti-CD20 Directed Therapy of B Cell Lymphomas: Are New Agents Really Better?
Ciara L. Freeman, Laurie H. Sehn
Current Oncology Reports (2018) Vol. 20, Iss. 12
Closed Access | Times Cited: 14
The Influence of Different Disease States on Rituximab Pharmacokinetics
Xiaoxing Wang, Wenwen Du, Xianglin Zhang, et al.
Current Drug Metabolism (2020) Vol. 21, Iss. 12, pp. 938-946
Closed Access | Times Cited: 12
Antibody desolvation with sodium chloride and acetonitrile generates bioactive protein nanoparticles
Levi Collin Nelemans, Vinicio Melo, Matěj Buzgo, et al.
PLoS ONE (2024) Vol. 19, Iss. 3, pp. e0300416-e0300416
Open Access | Times Cited: 1
Subcutaneous checkpoint inhibition is equivalent to systemic delivery when combined with nelitolimod delivered via pressure-enabled drug delivery for depletion of intrahepatic myeloid-derived suppressor cells and control of liver metastases
Chandra C. Ghosh, Lauren Cournoyer, Yujia Liu, et al.
Journal for ImmunoTherapy of Cancer (2024) Vol. 12, Iss. 7, pp. e008837-e008837
Open Access | Times Cited: 1
Real-world costs of illness of Hodgkin and the main B-Cell Non-Hodgkin lymphomas in France
Michaël Mounié, Nadège Costa, Cécile Conte, et al.
Journal of Medical Economics (2019) Vol. 23, Iss. 3, pp. 235-242
Open Access | Times Cited: 9
Population Pharmacokinetics and Exposure–Response Analyses for Venetoclax in Combination with R-CHOP in Relapsed/Refractory and Previously Untreated Patients with Diffuse Large B Cell Lymphoma
Divya Samineni, Weize Huang, Leonid Gibiansky, et al.
Advances in Therapy (2021) Vol. 39, Iss. 1, pp. 598-618
Open Access | Times Cited: 8
Development pathways for subcutaneous formulations of biologics versus biosimilar development
Artem Zharkov, Bettina Barton, Dominik Heinzmann, et al.
Expert Review of Precision Medicine and Drug Development (2019) Vol. 7, Iss. 1, pp. 62-69
Open Access | Times Cited: 8
Page 1 - Next Page

Scroll to top